Enhancing the efficacy of cisplatin in ovarian cancer treatment - Could arsenic have a role

Journal of Ovarian Research

Volumn 2, Issue 1, 2009, Pages

  Helm, C William ^a   States, J Christopher ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; APHIDICOLIN; ARSENIC; ARSENIC TRIOXIDE; BUTHIONINE SULFOXIMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESISTANCE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; DRUG UPTAKE; EPITHELIAL OVARIAN CANCER; GASTROINTESTINAL TOXICITY; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECURRENT CANCER; VOMITING;

EID: 77953456193     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-2-2     Document Type: Article

References (91)

1. Global Cancer Statistics. DM Parkin F Bray J Ferlay, et al. CA Cancer J Clin 2005 55 74 108 15761078
2. Cancer Facts and Figures. AC Society, 2008
3. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). WP McGuire WJ Hoskins MF Brady, et al. Semin Oncol 1996 23 40 47 8941409
4. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study[see comment]. FM Muggia PS Braly MF Brady, et al. 2000 18 106 115 10623700
5. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study[see comment]. RF Ozols BN Bundy BE Greer, et al. J Clin Oncol 2003 21 3194 3200 10.1200/JCO.2003.02.153 12860964
6. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer[see comment]. [erratum appears in J Clin Oncol 1992 Sep, 10(9):1505]. DS Alberts S Green EV Hannigan, et al. J Clin Oncol 1992 10 706 717 1569443
7. The changing prognosis and treatment in cancer of the ovary. E Munnell, Am J Obstet Gynecol 1968 100 790 795 4296050
8. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. CT Griffiths, Nat Cancer Inst Monog 1975 42 101 104 1757-2215-2-2
9. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. SM Eisenkop RL Friedman HJ Wang, Gynecol Oncol 1998 69 103 108 10.1006/gyno.1998. 4955 9600815
10. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. WJ Hoskins BN Bundy JT Thigpen, et al. Gynecol Oncol 1992 47 159 166 10.1016/0090-8258(92)90100-W 1468693
11. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. F Guidozzi JH Ball, Gynecol Oncol 1994 53 326 330 10.1006/gyno.1994.1142 8206406
12. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. RE Bristow RS Tomacruz DK Armstrong, et al. J Clin Oncol 2002 20 1248 1259 10.1200/JCO.20.5.1248 11870167
13. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. WJ Hoskins WP McGuire MF Brady, et al. Am J Obstet Gynecol 1994 170 974 979 8166218
14. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? SM Eisenkop NM Spirtos, Gynecol Oncol 2001 82 489 497 10.1006/gyno.2001.6312 11520145
15. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. SC Rubin TC Randall KA Armstrong, et al. Obstet Gynecol 1999 93 21 24 10.1016/S0029-7844(98)00334-2 9916949
16. Platinum compounds: a new class of potent antitumour agents. B Rosenberg L VanCamp JE Trosko, et al. Nature 1969 222 385 386 10.1038/222385a0 5782119
17. Cisplatin and Its Analogues. SW Johnson JP Stevenson PJ O'Dwyer VT DeVita S Hellman SA Rosenberg, Philadelphia:Lippincott Williams and Wilkins 6 2001 376 388
18. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. E Cvitkovic J Spaulding V Bethune, et al. Cancer 1977 39 1357 1361 10.1002/1097-0142(197704)39:4<1357::AID-CNCR28203904023.0.CO;2-C 856436
19. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. DM Hayes E Cvitkovic RB Golbey, et al. Cancer 1977 39 1372 1381 10.1002/1097-0142(197704)39:4<1372::AID-CNCR28203904043.0. CO;2-J 856437
20. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group. HE Lambert RJ Berry, Br Med J (Clin Res Ed) 1985 290 889 893 3919831
21. Epithelial Ovarian Cancer. RF Ozols SC Rubin GM Thomas WJ Hoskins CA Perez RC Young, et al. Philadelphia:Lippincott Williams and Wilkins 2000 981 1057
22. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. DG Decker TR Fleming GD Malkasian Jr, et al. Obstet Gynecol 1982 60 481 487 6889714
23. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. G Omura JA Blessing CE Ehrlich, et al. Cancer 1986 57 1725 1730 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR28205709033.0.CO;2-J 3513943
24. Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. JP Neijt WW ten Bokkel Huinink ME van der Burg, et al. Lancet 1984 2 594 600 10.1016/S0140-6736(84) 90594-4 6147640
25. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. Group AOCT, 1991 303 884 893 1834291
26. Taxol: a novel investigational antimicrotubule agent. EK Rowinsky LA Cazenave RC Donehower, J Natl Cancer Inst 1990 82 1247 1259 10.1093/jnci/82.15. 1247 1973737
27. Paclitaxel (taxol). EK Rowinsky RC Donehower, 1995 332 1001 1014
28. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. WP McGuire EK Rowinsky NB Rosenshein, et al. 1989 111 273 279 2569287
29. Promotion of microtubule assembly in vitro by taxol. PB Schiff J Fant SB Horwitz, Nature 1979 277 665 667 10.1038/277665a0 423966
30. Taxol stabilizes microtubules in mouse fibroblast cells. PB Schiff SB Horwitz, Proc Natl Acad Sci USA 1980 77 1561 1565 6103535 10.1073/pnas.77.3.1561
31. Taxol binds to cellular microtubules. JJ Manfredi J Parness SB Horwitz, J Cell Biol 1982 94 688 696 6127342 10.1083/jcb.94.3.688
32. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. I Ringel SB Horwitz, J Natl Cancer Inst 1991 83 288 291 10.1093/jnci/83.4.288 1671606
33. Early studies with cisdiamine 1, 1, cyclobutane dicarboxylate platinum II. AH Calvert SJ Harland, 1982 9 140 6761010
34. A phase I and pharmacokinetic study of diamminecyclobutane- dicarboxylatoplatinum (NSC 241240). GA Curt JJ Grygiel BJ Corden, et al. Cancer Res 1983 43 4470 4473 6347373
35. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. BD Evans KS Raju AH Calvert, et al. Cancer Treat Rep 1983 67 997 1000 6315233
36. Preclinical studies identifying carboplatin as a viable cisplatin alternative. KR Harrap, Cancer Treat Rev 1985 12 Suppl A 21 33 10.1016/0305-7372(85)90015-5 3910219
37. Carboplatin: current status and future prospects. R Canetta K Bragman L Smaldone, 1988 15 17 2841021
38. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. K Aabo M Adams P Adnitt, et al. Br J Cancer 1998 78 1479 1487 9836481
39. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. PA Vasey GC Jayson A Gordon, et al. 2004 96 1682 1691 15547181
40. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. RI Dedrick CE Myers PM Bungay, et al. Canc Treat Rep 1978 62 1 11 626987
41. Intraperitoneal chemotherapy in the management of malignant disease. M Markman, Exp Rev Anticanc Ther 2001 1 142 148 10.1586/14737140.1.1.142
42. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer[see comment]. DS Alberts PY Liu EV Hannigan, et al. N Engl J Med 1996 335 1950 1955 10.1056/NEJM199612263352603 8960474
43. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group[see comment]. M Markman BN Bundy DS Alberts, et al. J Clin Oncol 2001 19 1001 1007 11181662
44. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. DK Armstrong BN Bundy L Wenzel, et al. N Engl J Med 2006 354 34 43 10.1056/NEJMoa052985 16394300
45. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. K Jaaback N Johnson, Cochrane Database Systemat Rev 2006 25 1 D005340 16437527
46. NCI Clinical Announcement For Preferred Method of Treatment for Advanced Ovarian Cancer. 2006 http://ctep.cancer.gov/resources/gcig/icaoa.html accessed October 25th 2008
47. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. A Eastman, Pharmacol Ther 1987 34 155 166 10.1016/0163-7258(87)90009-X 3317449
48. Cellular accumulation of the anticancer agent cisplatin: a review. DP Gately SB Howell, Br J Cancer 1993 67 1171 1176 8512802
49. Potential for therapy of drugs and hyperthermia. GM Hahn, Canc Res 1979 39 2264 2268 87263
50. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). RE Meyn PM Corry SE Fletcher, et al. Cancer Res 1980 40 1136 1139 7188882
51. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. DS Alberts YM Peng HS Chen, et al. J Nat Cancer Inst 1980 65 455 461 6931261
52. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. G Los MJ van Vugt HM Pinedo, Brit J Cancer 1994 69 235 241 8297720
53. Effect of hyperthermia on the number of platinum atoms binding to DNA of HeLa cells treated with 195mPt-radiolabelled cis-diaminedichloroplatinum(II). M Akaboshi Y Tanaka K Kawai, et al. Int J Radiat Biol 1994 66 215 220 10.1080/09553009414551121 8089631
54. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. PJ van de Vaart N van der Vange FA Zoetmulder, et al. Eur J Cancer 1998 34 148 154 10.1016/S0959-8049(97)00370-5 9624250
55. Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR? P Borst M Kool R Evers, Semin Cancer Biol 1997 8 205 213 10.1006/scbi.1997.0071 9441949
56. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. AK Godwin A Meister PJ O'Dwyer, et al. Proc Natl Acad Sci USA 1992 89 3070 3074 1348364 10.1073/pnas.89.7.3070
57. Augmantation of Adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian cancer cell lines by buthionine sulfoximine dediated glutathione depletion. T Hamilton M Winker K Louie, et al. 1985 34 2583 2586 4040369
58. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. P Dedon RE Borch, 1987 36 1955 1964 2954556
59. An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines. LK Hosking RD Whelan SA Shellard, et al. Biochem Pharmacol 1990 40 1833 1842 10.1016/0006-2952(90)90364-Q 2242017
60. Sensitisation of human ovarian carcinoma cells to cis- diamminedichloroplatinum (II) by amphotericin B in vitro and in vivo. M Kojima F Kikkawa H Oguchi, et al. Eur J Cancer 1994 30A 773 778 10.1016/0959-8049(94) 90291-7 7917536
61. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. SW Johnson RP Perez AK Godwin, et al. 1994 47 689 697 8129746
62. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. SW Johnson PA Swiggard LM Handel, et al. 1994 54 5911 5916 7954422
63. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). H Masuda T Tanaka H Matsuda, et al. Cancer Res 1990 50 1863 1866 2306738
64. The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells. EJ Katz PA Andrews SB Howell, 1990 2 159 164 2114928
65. Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro. WC Dempke SA Shellard AM Fichtinger-Schepman, et al. Carcinogenesis 1991 12 525 528 10.1093/carcin/12.3. 525 1901253
66. Mechanisms of action of arsenic trioxide. WH Miller Jr HM Schipper JS Lee, et al. 2002 62 3893 3903 12124315
67. Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts. A Hartwig UD Groblinghoff D Beyersmann, et al. 1997 18 399 405 9054635
68. Induction of gene amplification by arsenic. TC Lee N Tanaka PW Lamb, et al. 1988 241 79 81 3388020
69. Stress proteins induced by arsenic. LM Del Razo B Quintanilla-Vega E Brambila-Colombres, et al. 2001 177 132 148 11740912
70. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. EM Leslie A Haimeur MP Waalkes, 2004 279 32700 32708 15161912
71. Arsenite causes DNA damage in keratinocytes via generation of hydroxyl radicals. H Shi LG Hudson W Ding, et al. 2004 17 871 878 15257611
72. Oxidative stress and apoptosis in metal ion-induced carcinogenesis. H Shi LG Hudson KJ Liu, 2004 37 582 593 15288116
73. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. AM Ramos C Fernandez D Amran, et al. 2005 105 4013 4020 15665116
74. Arsenic in cancer therapy. J Hu J Fang Y Dong, et al. 2005 16 119 127 15655408
75. p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1. BF Taylor SC McNeely HL Miller, et al. 2006 318 142 151 16614167
76. Arsenite delays progression through each cell cycle phase and induces apoptosis following G2/M arrest in U937 myeloid leukemia cells. G McCollum PC Keng JC States, et al. 2005 131 877 887 15749342
77. Arsenite disrupts mitosis and induces apoptosis in SV40-transformed human skin fibroblasts. [erratum appears in Toxicol Appl Pharmacol 2002 Sep 1, 183(2):152]. JC States JJ Reiners Jr JG Pounds, et al. 2002 180 83 91 11969375
78. Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment, and cell cycle phase. MJ McCabe Jr KP Singh SA Reddy, et al. 2000 295 724 733 11046111
79. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. SP Cole KE Sparks K Fraser, et al. 1994 54 5902 5910 7954421
80. History of the development of arsenic derivatives in cancer therapy. S Waxman KC Anderson, 2001 2 3 10 11331434
81. Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Liu Y Lu Q Wu, et al. J Pharmacol Exp Ther 2008 326 363 368 10.1124/jpet.108.139543 18463319
82. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. MH Cohen S Hirschfeld S Flamm Honig, et al. 2001 6 4 11 11161223
83. Clinical trials referral resource. Clinical trials with arsenic trioxide. AJ Murgo WL McBee BD Cheson, 2000 14 206 211, 215-216 10736809
84. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. AJ Murgo, 2001 2 22 28 11331437
85. Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines. YH Du PC Ho YH Du, et al. Cancer Chemother Pharmacol 2001 47 481 490 10.1007/s002800100278 11459200
86. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. R Uslu UA Sanli C Sezgin, et al. 2000 6 4957 4964 11156257
87. Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line. J Bornstein S Sagi A Haj, et al. Gynecol Oncol 2005 99 726 729 10.1016/j.ygyno.2005.07.125 16243384
88. Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines. B Kong S Huang W Wang, et al. Int J Gynecol Cancer 2005 15 872 877 10.1111/j.1525-1438.2005.00251.x 16174238
89. Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. J Zhang B Wang, Gynecol Oncol 2006 103 199 206 10.1016/j.ygyno.2006.02.037 16624393
90. Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. M Baumgartner S Sturlan E Roth, et al. Int J Cancer 2004 112 707 712 10.1002/ijc.20462 15382055
91. Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma. W Wang SK Qin BA Chen, et al. 2001 7 702 705 11819858